(Q51553495)

7 April 2018

title

Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study. (English)

1 reference

7 April 2018

0 references

Drouin P

1

1 reference

7 April 2018

publication date

1 July 2000

1 reference

7 April 2018

Journal of Diabetes and its Complications

published in

1 reference

7 April 2018

volume

14

1 reference

7 April 2018

issue

4

1 reference

7 April 2018

page(s)

185-191

1 reference

7 April 2018

Implications of the United Kingdom Prospective Diabetes Study. American Diabetes Association

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900086-6

7 January 2021

The mode of action and clinical pharmacology of gliclazide: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900086-6

7 January 2021

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900086-6

7 January 2021

Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900086-6

7 January 2021

Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900086-6

7 January 2021

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900086-6

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900086-6

7 January 2021

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900086-6

7 January 2021

Rates of hypoglycemia in users of sulfonylureas.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2800%2900086-6

7 January 2021

10.1016/S1056-8727(00)00086-6

Identifiers

DOI

1 reference

7 April 2018

1 reference

7 April 2018